Literature DB >> 16233998

Irritable bowel syndrome: toward an understanding of severity.

Anthony Lembo1, Vanessa Z Ameen, Douglas A Drossman.   

Abstract

Irritable bowel syndrome (IBS) is a chronic disorder with symptoms that range in severity from mild and intermittent to severe and continuous. Although severity is a guiding factor in clinical decision making related to diagnosis and treatment, current guidelines related to IBS do not address the issue of severity. Recent data suggest that severity as a multidimensional concept, not fully explained by intensity of symptoms, has important clinical implications including health care utilization and health-related quality of life. Components of IBS severity include symptom intensity, time of assessment, whether the patient or physician makes the severity determination, the type of scale used to measure severity, and the degree of disability or impairment. Currently no consensus definition of IBS severity exists, although 2 validated scales of IBS severity have recently been published. Review of the literature suggests that the prevalence of severe or very severe IBS is higher than previously estimated with a range from 3%-69%. Individual IBS symptoms are important but are not sufficient to explain severity. Rather, severity has multiple components including health-related quality of life, psychosocial factors, health care utilization behaviors, and burden of illness. However, studies have not been adequately designed to determine the relative values of these factors in IBS severity.

Entities:  

Mesh:

Year:  2005        PMID: 16233998     DOI: 10.1016/s1542-3565(05)00157-6

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  32 in total

Review 1.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

2.  Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report.

Authors:  Brennan Spiegel; Michael Camilleri; Roger Bolus; Viola Andresen; William D Chey; Sheri Fehnel; Allen Mangel; Nicholas J Talley; William E Whitehead
Journal:  Gastroenterology       Date:  2009-08-23       Impact factor: 22.682

3.  Latent structure of irritable bowel syndrome symptom severity.

Authors:  Fabian Jasper; Boris Egloff; Andrea Roalfe; Michael Witthöft
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

4.  Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.

Authors:  Prashant Singh; Kyle Staller; Kenneth Barshop; Elaine Dai; Jennifer Newman; Sonia Yoon; Shahar Castel; Braden Kuo
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

5.  Chronic prenatal stress epigenetically modifies spinal cord BDNF expression to induce sex-specific visceral hypersensitivity in offspring.

Authors:  J H Winston; Q Li; S K Sarna
Journal:  Neurogastroenterol Motil       Date:  2014-03-04       Impact factor: 3.598

6.  Adequate relief in a treatment trial with IBS patients: a prospective assessment.

Authors:  Maria C F Passos; Anthony J Lembo; Lisa A Conboy; Ted J Kaptchuk; John M Kelly; Mary T Quilty; Catherine E Kerr; Eric E Jacobson; Rong Hu; Elizabeth Friedlander; Douglas A Drossman
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

7.  Reply.

Authors:  Yong Sung Kim; Suck Chei Choi
Journal:  J Neurogastroenterol Motil       Date:  2010-04-28       Impact factor: 4.924

8.  Mechanisms of protease-activated receptor 2-evoked hyperexcitability of nociceptive neurons innervating the mouse colon.

Authors:  Ahmed Kayssi; Silvia Amadesi; Francisco Bautista; Nigel W Bunnett; Stephen Vanner
Journal:  J Physiol       Date:  2007-02-08       Impact factor: 5.182

9.  International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit.

Authors:  Douglas A Drossman; Carolyn Blank Morris; Susan Schneck; Yuming J B Hu; Nancy J Norton; William F Norton; Stephan R Weinland; Christine Dalton; Jane Leserman; Shrikant I Bangdiwala
Journal:  J Clin Gastroenterol       Date:  2009-07       Impact factor: 3.062

10.  The narcotic bowel syndrome: clinical features, pathophysiology, and management.

Authors:  David M S Grunkemeier; Joseph E Cassara; Christine B Dalton; Douglas A Drossman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.